Understand the pharmacology of T cell engaging molecules and the spectrum of safety liabilities resulting from their mode of action  

Specific challenges for in vivo nonclinical safety studies performed with TCEs i.e. sampling schedules, cytokine release, ADAs, on-target off-tumor toxicity 

Typical nonclinical pharmacology and toxicology package required to support FIH studies and BLA submission 

Current hot topics in the development of TCEs i.e. requirement for 3-month studies, studies required for well-characterized targets, use of surrogate molecules, transgenic animal models